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Abstract
In this report, we demonstrate the existence of the ubiquitin fold modifier-1 (Ufm1) and its conjugation pathway in
trypanosomatid parasite Leishmania donovani. LdUfm1 is activated by E1-like enzyme LdUba5. LdUfc1 (E2) specifically
interacted with LdUfm1 and LdUba5 to conjugate LdUfm1 to proteinaceous targets. Mass spectrometry analysis revealed
that LdUfm1 is conjugated to Leishmania protein targets that are associated with mitochondria. Immunofluorescence
experiments showed that Leishmania Ufm1, Uba5 and Ufc1 are associated with the mitochondria. The demonstration that
all the components of this system as well as the substrates are associated with mitochondrion suggests it may have
physiological roles not yet described in any other organism. Overexpression of a non-conjugatable form of LdUfm1 and an
active site mutant of LdUba5 resulted in reduced survival of Leishmania in the macrophage. Since mitochondrial activities
are developmentally regulated in the life cycle of trypanosomatids, Ufm1 mediated modifications of mitochondrial proteins
may be important in such regulation. Thus, Ufm1 conjugation pathway in Leishmania could be explored as a potential drug
target in the control of Leishmaniasis.
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Introduction
Leishmaniasis is a spectrum of diseases caused by protozoan
parasites belonging to several different Leishmania species. These
blood borne pathogens are currently prevalent in 88 countries
around the World with an estimated 2 million new cases each year
[1]. At present there are no effective vaccines against any of the
clinical forms of leishmaniasis. Currently available therapeutic
regimens are often limited in effectiveness due to unwarranted side
effects and rapidly emerging drug resistance. Therefore, the quest
for a novel vaccine and therapeutic targets acquires urgency
towards controlling leishmaniases.
Gene expression regulation in eukaryotic cells occurs at various
levels. In addition to initiation of transcription and post-
transcriptional changes, a wide range of post-translational
modifications are known to occur in eukaryotic cells. Collectively,
these modifications greatly expand the functional diversity of the
proteome. For this reason, protein modifications by ubiquitin and
ubiquitin like proteins continue to be an intensely studied
phenomenon [2]. The classical ubiquitin, a 8.6 kDa protein is
conjugated to its substrate protein through a complex cascade of
enzymatic reactions and signals targeting the protein to the
proteasome for degradation [3]. Apart from ubiquitin, a growing
list of small ubiquitin like proteins called Ubls is being discovered
[4]. These Ubls possess essentially the same three dimensional
structures as ubiquitin and employ mechanisms that generally
follow the ubiquitin prototype for conjugation to protein
substrates. These Ubls regulate a variety of biological functions
ranging from endocytosis, membrane trafficking, protein kinase
activation, DNA repair and chromatin dynamics [5,6].
The diversity of functions regulated by the Ubls in eukaryotic
organisms in general and the fact that inhibitors of the ubiquitin-
proteasome pathway are either in clinical use [7] or are being
studied for their potential as anticancer drugs [8,9] suggests that it
may be important to study these pathways in human parasitic
organisms. Hence, systematic studies of Ubl pathways in the
human trypanosomatid parasites such as Leishmania could yield
better understanding of the pathogenesis on one hand and
importantly could lead to novel therapeutic reagents. In Leishmania,
most of gene expression regulation occurs post-transcriptionally
[10]. Earlier studies on ubiquitin in trypanosomatid parasites such
as T. brucei and T. cruzi focused on revealing the ubiquitin gene
structure [11,12], ubiquitin-dependent protein degradation [13,14]
and its role in differentiation from trypomastigote into an
amastigote [15,16]. Developmental regulation of polyubiquitin
genes has been reported in Plasmodium [17]. Studies in Plasmodium
identified deubiquitinating/deNeddylating activities [18] and
sumoylation of telomere associated protein PfSir2, a novelsubstrate
protein for SUMO [19]. Recent studies have demonstrated the role
of ubiquitylation in the degradation of transmembrane surface
proteins in trypanosomes [20], cell cycle regulation by the single
SUMO homolog in T. brucei [21] and interactions with several
nuclear proteins in the host cell by a protein that possesses an
ubiquitin ligase activity secreted by T. cruzi [22]. However, even
after completion of the genome sequencing of several of the
trypanosomatid parasites, studies elucidating Ubl pathways, their
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modifications to the parasite proteome are absent. A recent review
catalogued several of the Ubls and their deconjugating enzymes in
parasitic protozoa including Leishmania and Trypanosoma [23].
Recently, a novel Ubl named ubiquitin-fold modifier 1 (Ufm1)
that conjugates to target protein(s) has been identified in
mammalian cells [24]. Ufm1 is synthesized as a precursor and a
C-terminal cleavage reaction involving specific cysteine proteases,
UfSP1 and UfSP2, exposes the conserved single glycine residue
[25]. The mature Ufm1 thus generated is activated by a specific
E1-like enzyme, Uba5, transferred to an E2- like enzyme, Ufc1,
and ligated to the only substrate protein identified so far
C20orf116, by a E3-like ligase Ufl1 [26]. However, the biological
roles of the Ufm1-modification of cellular proteins remain
unknown in part because of the difficulty in identification of the
substrate proteins. In this report we demonstrate the presence of
the Ufm1 pathway in the unicellular trypanosomatid parasite
Leishmania donovani. We have identified the putative genes encoding
the Ufm1, Uba5 and Ufc1 proteins and demonstrated the
activities of Leishmania encoded Uba5 and Ufc1. We demonstrated
for the first time the presence of Ufm1 modification pathway and
the protein targets in the mitochondria. We also showed that
modification/alteration of Ufm1 or Uba5 expression results in
reduced survival of Leishmania donovani in infected human
macrophages suggesting their role in Leishmania pathogenesis.
Results
Identification of genes encoding putative Ufm1 proteins
in trypanosomatid genomes
Parasitic protozoan organisms including Leishmania, Trypanosoma
and Plasmodium have complex life cycles and typically involve
invertebrate and vertebrate hosts. As a consequence, several of the
life-cycle transitions in these parasites must be accompanied by well
regulated changes in their protein functions. Recent discoveries in
the Ub and Ubl biology and the diversity of functions the Ubls
regulate by means of protein modifications rekindled an interest in
Ubl pathways in the parasitic organisms. Our previous studies
analyzing life-cycle associated gene expression patterns in Leish-
mania donovani employing a genomic microarray revealed a gene
fragment encoding a ,43 kDa protein to be abundantly expressed
in the amastigote stage of the parasite [27]. Bioinformatic analysis
revealed that this L. donovani ,43 kDa protein is homologous to
human Uba5. Since human Uba5 has been shown to be the
activating enzyme for Ufm1, we further searched trypanosomatid
genomes and identified genes encoding putative Ufm1 proteins in
the genome databases of Leishmania infantum (LinJ16_V31100) and
Trypanosoma brucei (Tb927.8.5380). We PCR amplified a putative
gene for Ufm1 from L. donovani genomic DNA. The predicted open
reading frame of L. donovani Ufm1 encodes a ,12.5 kDa protein
that possesses a 17 aminoacid residue extension at the C-terminus
where as the putative Ufm1 proteins in T. brucei and T. cruzi do not
have this extension, similar to the human Ufm1 protein as seen by
alignment of the trypanosomatid aminoacid sequences with the
human sequence (Figure S1). A comparison of trypanosomatid
Ufm1 aminoacid sequences with the human ortholog showed
several blocks of conserved aminoacid residues including the C-
terminal Gly which is important for conjugation to substrate
proteins in several Ubls [4]. Overall, primary aminoacid sequence
comparison revealed that Leishmania and Trypanosoma Ufm1
proteins display ,60% identity with human Ufm1.
A comparison of the putative trypanosomatid Uba5 aminoacid
sequences with the human ortholog showed several blocks of
conserved aminoacid residues (Figure S2). Overall, primary
aminoacid sequence comparison revealed that Leishmania and
Trypanosoma Uba5 proteins display ,50% identity with human
Uba5. Further analysis of the L. donovani putative homolog of
human Uba5 revealed it has an ATP-binding motif also common
in other trypanosomatid parasites and is similar to human Uba5
and other E1-like enzymes (Figure S2). In addition, a metal
binding motif shared by many E1-like enzymes such as human
Uba5, Uba2, Uba3, Uba4 and Atg7 and an active site Cys residue
occurring downstream of the metal binding motif was also found
in trypanosomatid Uba5 (Figure S2). Together, sequence homol-
ogy and conservation of catalytically important residues in the
putative Ufm1 and also in Uba5 suggested that trypanosomatid
genomes contain genes encoding some of the components of Ufm1
conjugation machinery. Therefore, we explored the biochemical
characteristics of Ufm1 mediated protein modification machinery
in Leishmania.
LdUba5 interacts with LdUfm1 and displays E1 activity
To investigate if the Leishmania Ufm1 undergoes enzymatic
processing prior to the activation by Uba5 as demonstrated in
human Ufm1 [24], Leishmania transfectants were prepared that
overexpress either the full length LdUfm1 (Ufm1
WT) or a mutant
in which the C-terminal Gly is changed to Ala (Ufm1
G98A)o ra
variant of LdUfm1 in which 18 aminoacid residues at the C-
terminus were removed including Gly 98 and therefore will not
undergo processing (Ufm1
DC). These transfectants carried an N-
terminal HA-epitope tag. Immunoblotting with total lysates from
these transfectants indicated that the exogenously expressed wild
type Ufm1 indeed undergoes processing as revealed by its faster
migration on the SDS-PAGE gel compared to Ufm1
G98A
(Figure 1A) as was observed in the analysis of human Ufm1
[24]. The Ufm1
DC showed the fastest migration as can be
expected and the wild type endogenously expressed Ufm1 (WT)
did not show any reactivity with a-HA antibodies (Figure 1A).
These results indicated that LdUfm1 undergoes enzymatic
processing prior to activation and suggested the existence of an
Ufm1 processing C-hydrolase activity in L. donovani.
It has been shown in many of the E1 and E1-like enzymes
cysteine residue in the active site is important for its activation and
interaction with the corresponding Ubl. Also, it has been
demonstrated that changing the cysteine residue in the active site
to serine results in formation of stable intermediates between the
E1 and its respective modifier protein [24]. This stable
intermediate is resistant to reducing agents and would be detected
as a high molecular weight product on an immunoblot. To
determine if the putative LdUba5 indeed can interact with
LdUfm1 and activate it, Leishmania transfectants that overexpress
either wild type Uba5 or mutants in the putative catalytic site
(Cys217Ser or Cys217Ala) were prepared. The Cys217Ala Uba5
mutant was developed to serve a control for the Cys217Ser
mutant. The wild type Uba5 and Uba5
C217A mutant carried a C-
terminal HA-epitope tag where as the Uba5
C217S mutant carried
an N-terminal HA-epitope tag. To identify the endogenous
LdUba5, polyclonal antibodies were raised against the recombi-
nant LdUba5 protein. These antibodies identified a distinct
,43 kDa band in the L. donovani lysates (Figure 1B). Further, our
results showed that in immunoblots probed with anti-LdUba5
antibodies, a high molecular weight intermediate was detectable
only in cells overexpressing the LdUba5
C217S mutant (Figure 1C,
indicated with *). These cells also express the endogenous wild
type LdUba5 migrating as the lower molecular weight band
(Figure 1C, indicated by arrowhead). In the cells expressing
LdUba5
C217A or wild type Uba5
WT the high molecular weight
intermediate was not found (Figure 1C). An anti-HA immunoblot
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exogenously expressed LdUba5 variants to be comparable
(Figure 1C). The high molecular weight intermediate observed
in the LdUba5
C217S mutant with anti-LdUba5 antibodies was also
evident in the anti-HA immunoblot (Figure 1C). These results
suggest the conservation in the mechanism of LdUba5 similar to
that found in other Ubl activating enzymes.
To verify that LdUfm1 is the endogenous protein with which
LdUba5 forms a high molecular weight intermediate in the
C217S mutant, Leishmania transfectants that co-express LdUfm1 in
either wild type LdUba5 or LdUba5
C217S or LdUba5
C217A mutant
background were prepared. The LdUfm1 overexpression con-
struct carried an HA-epitope and 6xHis tags at the N-terminus.
The lysates from these transfectants were first probed with
a-LdUba5 antibodies and the immunoblot (Figure 1D) showed
that these co-expressors showed a similar expression pattern to
single expressors as shown in Fig. 1C. When the immunoblots
were probed with an a-His antibody which will recognize only
LdUfm1, a ,60 kDa band was apparent only in the transfectant
co-expressing LdUfm1 and LdUba5
C217S (Figure 1D a-His,
indicated with *). This result demonstrated that in the LdU-
ba5
C217S mutant, LdUfm1 co-expressed protein is part of the high
molecular weight intermediate (Figure 1D). To further confirm
this interaction between LdUba5 and LdUfm1, we expressed wild
type and mutant forms of LdUfm1 and performed coimmuno-
precipitation experiments (Figure 1E). Protein lysates from
Leishmania transfectants expressing either wild type or mutant
forms of Ufm1 (Ufm1
G98A, Ufm1
DC) containing HA-epitope tag
were incubated with anti-HA affinity gel and the immunoprecip-
itated material was resolved on SDS-PAGE and the immunoblots
were probed with anti-LdUba5 antibodies. The results showed
that LdUba5 protein can be precipitated with all three forms of
LdUfm1 indicated by the specific ,43 kDa band in all the
transfectants except in untransfected Leishmania cells that do not
express Ha-tagged Ufm1 (Figure 1E) even though such molecular
interactions are known to be transient in other Ubls. Conversely,
when protein lysates from these cells expressing either wild type or
mutant forms of Ufm1 (Ufm1
G98A, Ufm1
DC) were immunopre-
cipitated with anti-LdUba5 antibodies and the immunoblots from
the immunoprecipitated material were probed with anti-HA that
recognizes LdUfm1 protein or its mutant forms, 10–16 kDa bands
representing the size of Ufm1 proteins were observed (Figure 1F)
as was seen previously (Figure 1A).
To verify whether LdUba5 not only interacts with LdUfm1 but
possesses E1-like activity, an end point fluorescence polarization
assay was utilized. We tested wild type Leishmania Uba5 and
LdUba5
C217A proteins for the E1-like activity using either wild
type LdUfm1 or the mutant LdUfm1
G98A as substrates. The wild
type LdUfm1 used in this assay contained Gly98 as the C-terminal
residue and therefore would appear as mature LdUfm1. Similar to
LdUba5 proteins, HA-epitope tag containing LdUfm1 variants
were also immunoprecipitated from corresponding Leishmania
transfectants using an a-HA affinity gel. The results showed that
E-1 like activity was evident only when wild type LdUba5 and wild
type mature LdUfm1 along with ATP were present in the reaction
and in the presence of either LdUba5 or LdUfm1 mutants such
activity was not detected (Figure 2A). On the other hand, in the
absence of ATP, there was no detectable E-1 like activity with wild
type LdUba5 and wild type mature LdUfm1 (Figure 2A). To test
whether LdUba5 can activate mature human Ufm1 and thus
functionally complement human Uba5, we used recombinant
mature human Ufm1 with either wild type LdUba5 or
LdUba5
C217A proteins immunoprecipitated from the respective
Leishmania transfectants with a-HA affinity gel. Results showed that
wild type LdUba5 can activate human Ufm1 as measured by the
decreased fluorescence polarization observed only in the wild type
LdUba5 but absent in the LdUba5
C217A protein (Figure 2B). In
control experiments, we tested human Uba5 and human Ufm1 in
a similar activation assay. Results showed that human recombi-
nant Uba5 displays E-1 like activity only when all the components
i.e., Uba5, Ufm1 and ATP are present (Figure 2C). Together,
these results clearly established the E-1 like activity of LdUba5 and
activation of LdUfm1. Furthermore, LdUba5 can complement
human Uba5 in an in vitro assay for E1 like activity.
LdUfc1 interacts with LdUfm1
Existence of a functional LdUfm1and its activating enzyme
LdUba5 that has E1-like activity indicated that other components
such as conjugating enzymes might also be present in the
trypanosomatid parasites. Bioinformatic analysis using human
Ufc1 protein that has been previously shown to be the conjugating
enzyme of human Ufm1 [24] allowed us to identify genes
Figure 1. Protein-protein interactions between LdUba5 and LdUfm1. (A) Exogenous expression of Wild type LdUfm1 and the mutant forms.
Leishmania transfectants overexpressing either wild type full length Ufm1 (Ufm1
WT) or truncated form in which 18 aminoacid residues at the C-
terminus including Gly
98 were removed (Ufm1
DC) or the mutant form in which the putative cleavage site Gly 98 is altered (Ufm1
G98A) were prepared.
The transfectants Ufm1
WT, Ufm1
DC and Ufm1
G98A carried an HA epitope tag at the N-terminus. Protein lysates from equal number of the transfectants
(Uba5
WT, Uba5
C217S and Uba5
C217A) and L. donovani wild type parasites (WT) were resolved on SDS-PAGE and probed with anti-HA antibodies (a-HA).
(B) IgG fraction enriched from the polyclonal antibodies raised against L. donovani Uba5 protein were reacted with promastigote L. donovani lysates
(a-LdUba5) in an immunoblot. Pre-immune serum was used as a control (NRS). (C) Leishmania transfectants overexpressing either wild type Uba5
(Uba5
WT) or the mutant forms (Uba5
C217S, Uba5
C217A) in which the predicted active site Cys was changed to either Ser or Ala by PCR were prepared.
The transfectants Uba5
WT and Uba5
C217A possessed an HA epitope tag at the C-terminus while in the Uba5
C217S mutant, the HA tag was at the N-
terminus. Protein lysates from equal number of L. donovani wild type parasites (WT) and the transfectants (Uba5
WT, Uba5
C217S and Uba5
C217A) were
resolved on SDS-PAGE and probed with either with polyclonal antibodies raised against LdUba5 (a-LdUba5) or with anti-HA antibodies (a-HA). (D)
Identification of the stable intermediate linked to LdUba5 in Leishmania transfectant cells. Leishmania transfectants overexpressing Ufm1 containing
both 6xHis and HA tags at the N-terminus (Ufm1
WT) or co-expressing Ufm1
WT and either wild type Uba5 (Uba5
WT) or the mutant forms (Uba5
C217S,
Uba5
C217A) were prepared. Protein lysates from equal number of L. donovani transfectants expressing Ufm1
WT alone or co-expressing variants of Uba5
(Uba5
WT, Uba5
C217S and Uba5
C217A) were resolved on SDS-PAGE and probed with either with polyclonal antibodies raised against LdUba5 (a-LdUba5)
or with anti-His antibodies (a-His). (E) Immunoblot analysis following immunoprecipitation reactions. Protein lysates from wild type L. donovani cells
(WT) or transfectants expressing variants of LdUfm1 (Ufm1
WT, Ufm1
G98A or Ufm1
DC) were used in co-immunoprecipitation reactions with a-HA affinity
gel and the eluates were resolved on SDS-PAGE and the immunoblots were probed with anti-LdUba5 antibodies (a-LdUba5). Ponceau-S stained
immunoblot showing the heavy chain IgG (IgG H/C) to indicate the amount of antibodies used in immunoprecipitation reactions. The immunoblot of
the total lysates with a-LdUba5 antibodies indicating equal amounts of lysates used in immunoprecipitation reaction is shown. (F) Conversely, protein
lysates from wild type L. donovani cells (WT) or transfectants (Ufm1
WT, Ufm1
G98A or Ufm1
DC) were used in co-immunoprecipitation reactions with a-
LdUBA5 antibodies and the immunoblots were probed with anti-HA antibodies (a-HA). Ponceau-S stained immunoblot showing the heavy chain IgG
(IgG H/C) to indicate the amount of antibodies used in immunoprecipitation reactions.
doi:10.1371/journal.pone.0016156.g001
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infantum (LinJ15_V3.1270), Trypanosoma brucei (Tb09.160.4150) and
Trypanosoma cruzi (Tc00.1047053506445.100). A comparison of the
putative trypanosomatid Ufc1 aminoacid sequences with the
human ortholog showed several blocks of conserved aminoacid
residues including the Cys115 residue which has been shown to be
the active site in human Ufc1 (Figure S3 indicated by *). Overall,
primary aminoacid sequence comparison revealed that Leishmania
and Trypanosoma Ufc1 proteins display ,60% identify with human
Ufc1. To ascertain if the putative LdUfc1 can interact with
LdUfm1 for conjugation to potential protein targets, the putative
Ufc1 coding sequence was amplified from the L. donovani genome
and cloned into an expression vector. Leishmania transfectants that
overexpress full length LdUfc1 alone or coexpress LdUfc1 and
LdUfm1 proteins were prepared. The full length LdUfc1 carried a
C-terminal FLAG-epitope tag where as the LdUfm1 carried an N-
terminal HA-epitope tag. To detect the molecular interaction
between these proteins, we performed coimmunoprecipitation
experiments. Immunoprecipitation reactions followed by immu-
noblotting using lysates from the transfectants showed that the
Figure 2. Demonstration of E1-like activity of LdUba5 and activation of LdUfm1. (A) Activation of Leishmania Ufm1 by LdUba5. Leishmania
Ufm1 lacking the 17 aminoacid residues at the C-terminus and thus exposing the terminal Gly residue and a mutant Ufm1 in which the terminal Gly is
changed to Ala were immunoprecipitated from the respective Leishmania transfectants were incubated with either wild type LdUba5 or LdUba5
C217A
proteins immunoprecipitated from the corresponding Leishmania transfectants in the combinations indicated either with or without ATP and
changes in the magnitude of fluorescent polarization are measured. Leishmania proteins from LdUba5, LdUba5
C217A, LdUfm1 or LdUfm1
G98A
transfectants were included as background controls. The data are collected from three independent experiments. Error bars indicate the standard
deviation. (B) Activation of human Ufm1 by LdUba5. Human Ufm1 was incubated with either wild type LdUba5 or LdUba5
C217A proteins
immunoprecipitated from the corresponding Leishmania transfectants and ATP and changes in the magnitude of fluorescent polarization are
measured. Leishmania proteins from LdUba5 or LdUba5
C217A transfectants without human Ufm1 were included as background controls. (C) Human
recombinant Uba5 and Ufm1 proteins were incubated either in the presence or absence of ATP and changes in the magnitude of fluorescent
polarization in the tracer molecule are measured indicating the activity of Uba5.
doi:10.1371/journal.pone.0016156.g002
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presence of the nearly ,26 kDa LdUfc1 protein only in the
transfectants that express both LdUfm1 and LdUfc1 and not when
either of the epitope tagged proteins is expressed alone (Figure 3A,
indicated by arrow). This result showed that the LdUfc1 can
interact with LdUfm1 and potentially carry out the conjugation
reaction. To test whether a molecular interaction could be
detected between the endogenous LdUba5 and transfected
LdUfc1, similar to human Uba5 and Ufc1, lysates from
transfectants expressing LdUfm1, LdUfc1 alone or expressing
both proteins were used in a coimmunoprecipitation reaction
using a-LdUba5 antibodies followed by immunoblotting with a-
FLAG antibody which recognizes LdUfc1. The result showed that
FLAG tagged LdUfc1 can be detected in an immunoblot both in
LdUfc1 transfectants and those expressing the combination of
LdUfc1 and LdUfm1 (Figure 3B, indicated by arrow) but not in
the untransfected L. donovani lysates (Figure 3B). On the other
hand, when a-FLAG antibodies were used in the immunoprecip-
itation reaction, LdUfc1 could pull down endogenous LdUba5
protein as shown by the immuno-reactive ,43 kDa band on the
immunoblot using LdUba5 antibodies (Figure 3C, indicated by
arrow). Together, these results demonstrate that LdUba5 and
LdUfc1 can independently interact with LdUfm1 and also can be
found in a molecular complex with all three components.
Role of Ufm1 and Uba5 in the parasite pathogenesis
To further investigate the role of LdUfm1 conjugation on the
differentiation and survival of intracellular amastigotes, human
macrophages derived from elutriated monocytes were infected with
wild type stationary phase Leishmania promastigotes or those
overexpressing either wild-type LdUfm1 or variants of LdUfm1
(Ufm1
G98A, Ufm1
DC) according to previously published protocol
[28]. No difference in the number of amastigotes per hundred
macrophages was found between wild type control cells or
transfectants expressing either wild type Ufm1 or Ufm1
DC except
parasites overexpressing the LdUfm1
G98A mutant. Over-expres-
sion of LdUfm1
G98A resulted in reduction in number of Leishmania
amastigotes in the macrophages after 72 hours of infection. This
reduction in parasite number is significant compared to control
cells (WT) and LdUfm1
WT and LdUfm1
DC transfectants (p,0.005,
Figure 4A). The reduction in amastigote number in LdUfm1
G98A
mutants suggests that over-expression of non-processed Ufm1
probably disrupts the regulation of Ufm1 conjugation and also
competes with the wild type Ufm1 for conjugation/deconjugation
Figure 3. Expression of LdUfc1, the conjugating enzyme of Ufm1 in Leishmania and protein interactions between LdUfc1, LdUba5
and LdUfm1. (A) Immunoblot analysis following immunoprecipitation reactions. Protein lysates from wild type L. donovani cells (WT) or
transfectants expressing either the putative LdUfc1 with a FLAG epitope or LdUfm1 or coexpressing the putative LdUfc1 and LdUfm1 were used in
co-immunoprecipitation reactions with a-HA affinity gel and the eluates were resolved on SDS-PAGE and the immunoblots were probed with anti-
FLAG antibodies. The immunoblot of the total lysates with a-FLAG antibodies indicating equal amounts of lysates used in immunoprecipitation
reaction is shown (arrow head). (B) Immunoblot analysis following immunoprecipitation reactions. Protein lysates from wild type L. donovani cells
(WT) or transfectants expressing either the putative LdUfc1-FLAG or LdUfm1 or coexpressing the putative LdUfc1-FLAG and LdUfm1 were used in co-
immunoprecipitation reactions with a-LdUba5 antibodies and the eluates were resolved on SDS-PAGE and the immunoblots were probed with anti-
FLAG antibodies. The bands corresponding to LdUfc1 are indicated with arrow mark. Ponceau-S stained immunoblot showing the heavy chain IgG
(IgG H/C) to indicate the amount of antibodies used in immunoprecipitation reactions. (C) Conversely, protein lysates from wild type L. donovani cells
(WT) or transfectants expressing either the putative LdUfc1-FLAG or LdUfm1 or coexpressing the putative LdUfc1-FLAG and LdUfm1 were used in co-
immunoprecipitation reactions with a-FLAG antibodies and the eluates were resolved on SDS-PAGE and the immunoblots were probed with anti-
LdUba5 antibodies. The bands corresponding to LdUba5 are indicated with arrow mark. Ponceau-S stained immunoblot showing the heavy chain IgG
(IgG H/C) to indicate the amount of antibodies used in immunoprecipitation reactions.
doi:10.1371/journal.pone.0016156.g003
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verify such disruption in regulation we performed Western blot
analysis of proteins conjugated with Ufm1 and its mutant forms
(Figure S4). We observed the loss of a subset of conjugated proteins
with Ufm1
G98A mutant and complete loss of conjugating proteins
with Ufm1
DC (Figure S4 compare lanes 2 and 3 with lane 1). It is
therefore possible that the G98A mutation confers resistance
against Ufm1 processing as shown in the figure 1A, and the protein
conjugates formed with Ufm1
G98A may remain stable that could
interfere with the function of the wild type Ufm1 and hence may
affect the growth of parasites as observed by the reduction of
parasite number in macrophages (Figure 4A). On the other hand,
since we did not observe conjugating proteins with Ufm1
DC,i ti s
possible that it may not interfere with the function of wild type
Ufm1 as was observed by the growth of parasites in macrophages
(Figure 4A). The interaction between LdUfm1 and LdUba5
C217S
mutant results in an irreversible complex formation and presum-
ably resulting in reduced Ufm1 availability (Figure 1D). Therefore,
we investigated the effects of active site mutations in the Uba5, the
Ufm1 activating enzyme, on parasite growth in human macro-
phage infection experiments. A significant reduction in the growth
of LdUba5
C217S mutant was observed in the macrophages
compared with either the wild type or transfectants overexpressing
wild type Uba5 or LdUba5
C217A mutant (Figure 4B). Together,
these results demonstrated that alterations in LdUfm1 conjugation
or indirectly mutations in LdUba5 affect the parasitic growth in the
human macrophages.
Mitochondrial localization of LdUfm1, LdUba5 and LdUfc1
The observation that all the LdUfm1 substrate proteins are
localized in the mitochondria led us to investigate the cellular
distribution of endogenous LdUfm1, LdUba5 and LdUfc1
proteins in Leishmania. To this end, antibodies against L. donovani
LdUba5 and LdUfc1 and T. brucei Ufm1 proteins were used in
immunofluorescence studies. There is a high degree of similarity
between LdUfm1 protein and its T. brucei homolog resulting in
cross reaction of LdUfm1 with the anti-TbUfm1 antibodies. An
immunoblot with affinity-purified anti-TbUfm1 antibodies specif-
ically recognized the unconjugated Ufm1 migrating at about
,12 kDa and in addition a ,50 kDa band, presumably an
LdUfm1 conjugate in L. donovani promastigote lysates (Figure 5A).
Immunofluorescence assays with these antibodies revealed that
endogenous LdUfm1 is localized in mitochondria in L. donovani
promastigotes, as indicated by its colocalization with Mitotracker
Red, a mitochondrial marker (Figure 5B, bottom panel). No
background reactivity was obtained with the pre-immune serum in
these experiments (Figure 5B, top panel). The pattern of
colocalization is likely to represent both the free pool of LdUfm1
and also the Ufm1 conjugated to the substrate proteins. We next
explored the localization of other components of the Ufm1
machinery i.e., LdUba5 and LdUfc1. Immunofluorescence assays
with the anti-LdUba5 antibodies revealed that endogenous
Leishmania Uba5 in promastigotes is also clearly localized in
mitochondria (Figure 5C, bottom panel). Very little fluorescent
signal was evident outside of mitochondria. No background
reactivity was obtained with the pre-immune serum (Figure 5C,
top panel). The LdUfc1 antibodies specifically reacted with a
,26 kDa protein in the wild type Leishmania promastigote lysates
(Figure 5D, lane a-LdUfc1). The pre-immune serum did not react
with any protein in the Leishmania lysates (Figure 5D, NRS).
Immunofluorescence assay with the anti-LdUfc1 antibodies
showed that endogenous Leishmania Ufc1 protein in promastigotes
is clearly localized in mitochondria (Figure 5E, bottom panel). No
fluorescent signal was observed outside of mitochondria. Control
staining with the pre-immune serum only showed background
reactivity (Figure 5E, top panel). Taken together the cellular
distribution of LdUfm1, LdUba5, LdUfc1 and the Ufm1
conjugated substrates in the mitochondria argues for a mitochon-
drion specific Ufm1 conjugation system in Leishmania.
LdUfm1 is conjugated to mitochondrial proteins
The existence of LdUba5 and LdUfc1 strongly indicated that
LdUfm1 mediated protein conjugation occurs in this parasite.
Direct conjugation by E2 enzymes to protein targets has been
Figure 4. In vivo effects of alterations in the LdUfm1/Uba5 expression on Leishmania growth. (A) Human macrophages differentiated
from monocytes were infected with purified metacyclic parasites from L. donovani wild type (WT) or transfectant cultures (Ufm1, Ufm1
G98A or Ufm1
DC)
for six hours (10:1 parasite-to-macrophage ratio) and the numbers of amastigotes in these cultures were determined over a period of 6 days by
microscopic observation of Diff-quik reagent stained slides. The data are expressed as the number of amastigotes per 100 macrophages. Error bars
indicate the standard deviation. (B) The growth of L. donovani wild-type (WT), or wild-type Uba5 (LdUba5) or mutant Uba5 transfectants (LdUba5
C217S
or LdUba5
C217A) amastigotes in human macrophages was monitored. The results are the mean of three independent experiments.
doi:10.1371/journal.pone.0016156.g004
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this reasoning, we investigated whether LdUfm1 conjugation
could occur with its substrates in Leishmania. We constructed HA
and 6xHis tag containing LdUfm1 that ends in the Gly98 residue
at the C-terminus and a variant of LdUfm1 which lacks a Gly
residue at the C-terminus and has instead Val97 as its terminal
residue. This mutant lacking the terminal Gly therefore must be
unable to conjugate to the protein targets in Leishmania and
therefore should serve as a background control. Using these
transfectants, LdUfm1 conjugates were purified using Nickel
agarose beads that bound the 6xHis tag in the transfected
LdUfm1. This purification was carried out under denaturing
conditions to avoid purifying proteins that interact non-covalently
with LdUfm1. Results showed that distinct Ufm1 conjugates from
promastigotes and axenic amastigotes were identified by a-Ufm1
antibody (Figure 6A) suggesting the subtle variations in the Ufm1
mediated conjugations that might accompany the parasitic
differentiation. Using similar protocol, we purified the Ufm1
conjugated for the purpose of identification by mass spectrometric
analysis. Results showed that several proteins with molecular
weights ranging from ,20 to ,100 kDa were detected only in the
transfectants expressing mature LdUfm1 but not in the transfec-
tants expressing the non-conjugatable LdUfm1 (Figure 6B). The
SDS-PAGE gel slices corresponding to these conjugates were
excised and in-gel tryptic digestion was performed followed by
reduction and alkylation reactions to generate peptides. The
peptides were analyzed by LC/MS and the product ion spectra
were searched against the non-redundant NCBI database and
Leishmania infantum GeneDB database (http://www.genedb.org/
genedb/leish/) using the Mascot search program. Out of the
multiple Leishmania proteins to which the tryptic peptides mapped
only those proteins where multiple peptides could be assigned are
shown (Figure 6C). The peptides in each protein identified came
from gel slices that had higher calculated molecular weight than
the predicted molecular weight of the identified protein suggesting
post translational modifications, possibly with LdUfm1. Our LC/
MS data identified two proteins 40S ribosomal protein SA (from
the gel slice corresponding to ,50 kDa) and mitochondrial
trifunctional protein a-subunit (from the gel slice corresponding
to ,95 kDa) with multiple peptides mapped to the corresponding
proteins. Interestingly, both these proteins have been shown to
have mitochondrial localization in trypanosomatids [30,31].
Taken together, these data demonstrate that for the first time a
unicellular organism such as the Leishmania parasites possesses the
full complement of Ufm1 mediated protein conjugation machinery
which seems to be functioning in the mitochondria.
Discussion
In this report we demonstrated the existence of an Ufm1
conjugation pathway in the human protozoan parasite Leishmania
donovani including the enzymatic steps involving activation by
Uba5 (E1), conjugation by Ufc1 (E2) and finally conjugation with
substrate proteins. Modification and/or alterations in the
expression of Ufm1 and Uba5 showed parasite stage specific
growth effects underlining the importance of Ufm1 mediated
protein modifications in Leishmania growth and differentiation.
Importantly all the components of Ufm1 conjugation and the
substrate proteins in Leishmania appear to be associated with the
mitochondria. To our knowledge this is the first demonstration of
a trypanosomatid mitochondrial associated complete Ubl pathway
in which the activation, conjugation components and the substrate
proteins are all localized in mitochondria.
Initial studies showed that the Ufm1 pathway is widely
conserved in mammals, nematode and other multicellular
organisms but absent in unicellular eukaryotes such as yeast
[24]. Our first of a kind demonstration of Ufm1 pathways in
trypanosomatid parasites, unicellular eukaryotes that emerged as
early eukaryotic organisms indicates the ancient origins of this
pathway. In trypanosomatid parasites, our analysis showed that
the Ubls such as Ub, SUMO and Ufm1 appear to have one or
more aminoacid residues after the C-terminal glycine that need to
be processed before conjugation (data not shown). Among the
trypanosomatids, only Leishmania Ufm1 has a longer C-terminal
extension that is 17 residues long. However, our results suggest
that in L. donovani C-terminal processing of Ufm1 does occur
suggesting the presence of a processing protease and the Gly98
residue is essential for that cleavage and subsequent conjugation.
In contrast, apicomplexan parasites such as Plasmodium contain
Ubls (Atg8) that terminate in a C-terminal Glycine indicating the
absence of processing prior to conjugation [23]. This structural
diversity among different parasites might be a result of adaptations
that parasites have undergone in their respective environments
during their complex life cycles.
Similar to humans, LdUba5 interacts with LdUfm1 and
activates it in an ATP dependent reaction. Also, biochemical
characteristics shared between human Uba5 and LdUba5 and
activation of human Ufm1 by LdUba5 demonstrated the
mechanistic similarities between the pathways in the two species.
Previously it has been demonstrated that human Ufm1 interacts
with its activating enzyme Uba5 involving the cysteine residue in
the active site [24]. Also, it has been shown in many of the E1 and
E1-like enzymes of Ub or Ubls that changing the cysteine residue
in the active site to serine results in formation of stable
intermediates between the E1 and its respective modifier protein.
Our studies showed that LdUba5
C217S mutant also makes a
stable intermediate with LdUfm1. The formation of stable
intermediate is likely due to the covalent ester link between
Uba5 and Ufm1 as previously observed in other E1-like enzymes
[24]. It is reasonable to expect overexpression of LdUba5
C217S
would have a negative dominant effect which will result in
depletion of the free pool of endogenous Ufm1. Interestingly,
overexpression of the LdUba5
C217S mutant resulted in significant
Figure 5. Immunofluorescence staining of L. donovani parasites with antibodies against LdUfm1, LdUba5 and LdUfc1. (A) Affinity
purified polyclonal antibodies raised against T. brucei Ufm1 protein reacted with promastigote L. donovani lysates (a-Ufm1) in an immunoblot. Only a
shorter exposure of the immunoblot is shown to avoid revealing the multiple faint bands resulting from Ufm1 conjugates. Pre-immune serum was
used as a control (NRS). (B) L. donovani promastigote cells were stained with antibodies against TbUfm1 (a-Ufm1) as primary, and Alexa488-
conjugated anti-rabbit IgG as secondary antibodies. To visualize mitochondria, cells were labeled with Mitotracker Red (Mito Red). The nucleus and
kinetoplast were stained with DAPI. Pre-immune serum (NRS) was used in control staining experiments. (C) L. donovani promastigote cells were
stained with IgG fraction enriched from anti-LdUba5 antiserum (a-LdUba5) as primary, and Alexa488-conjugated anti-rabbit IgG as secondary
antibodies. Mitochondria, nucleus and kinetoplast were stained as described above. Pre-immune serum (NRS) was used in control staining
experiments. (D) Affinity purified polyclonal antibodies raised against L. donovani Ufc1 protein were reacted with promastigote L. donovani lysates
(a-LdUfc1) in an immunoblot. Pre-immune serum was used as a control (NRS). (E) L. donovani promastigote cells were stained with antibodies against
LdUfc1 (a-LdUfc1) as primary, and Alexa488-conjugated anti-rabbit IgG as secondary antibodies. Mitochondria, nucleus and kinetoplast were stained
as described above. Pre-immune serum (NRS) was used in control staining experiments. Bars, 5 mm (B, C) 10 mm (E).
doi:10.1371/journal.pone.0016156.g005
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LdUfm1 conjugation in parasite pathogenesis (Figure 4B). Simi-
larly, protein interactions between LdUfm1 and LdUfc1 showed
the conservation of E2-like activity in L. donovani parasites, thereby
demonstrating the importance of E2 activity in the Leishmania
Ufm1 conjugation pathway as well as E1 activity. Recently,
human E3-ligase Ufl1 that conjugates Ufm1 to its substrate protein
was identified [26]. Database searches in the trypanosomatid
genomes indicated that these parasites may encode an ortholog of
human ufl1, albeit with low sequence homology. However, E3
ligase independent conjugation of Ubls via E2 activity is still a
distinct possibility as was recently reported [29].
Figure 6. Purification of LdUfm1 conjugates and identification of the peptides by mass spectrometric analysis. (A) Protein lysates
either from promastigote stage (Pro) or axenic amastigote (AxAm) stage Leishmania transfectant cells expressing either HA-His-Ufm1
WT or HA-His-
Ufm
DC were prepared under denaturing conditions and the conjugates were precipitated with Ni-agarose beads. The eluates from the beads were
subjected to SDS-PAGE and the immunoblots were probed with a-Ufm1 antibodies. Pre-immune serum (NRS) was used in control immunoblots. (B)
Leishmania transfectant cells expressing HA-His-Ufm1
WT or the non-conjugatable HA-His-Ufm
DC were lysed under denaturing conditions and the
conjugates were precipitated with Ni-agarose beads. The eluates from the beads were subjected to SDS-PAGE stained with Coomassie blue and
scanned on a LiCor odyssey instrument. The SDS-gel slices excised from the acrylamide gel for the purpose of peptide identification are indicated
with white arrow marks. (C) The identification of the peptides from the gel slices and the corresponding proteins to which the peptides map to are
listed. The asterisks (B and C) indicate the gel slices from which the peptides originated.
doi:10.1371/journal.pone.0016156.g006
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biological function to the Ufm1 pathway in any organism so far is
that the target proteins that are conjugated by Ufm1 have not
been characterized. Our LC/MS results showed that LdUfm1 is
potentially conjugated to the 40S ribosomal protein SA and the
mitochondrial trifunctional protein a-subunit. It is known that the
40S ribosomal protein SA is required for the assembly and/or
stability of the 40S ribosomal subunit. In L. tarentolae 40S ribosomal
subunits have been shown to be enriched in mitochondria [30]. A
role for Ubls in the regulation of either stability or activity of
mammalian ribosomal proteins was indicated by their conjugation
to NEDD [32].
The mitochondrial trifunctional protein catalyzes three consec-
utive reactions in the b-oxidation of long-chain fatty acids, and
plays important role in control and regulation of b-oxidation [33].
Fatty acid oxidation is an essential energy generation system that
occurs in mitochondria. In T. brucei, a trypanosomatid parasite
related to Leishmania, proteomic analysis revealed that the
mitochondrial trifunctional protein is enriched in the mitochon-
dria [31]. In trypanosomatids the regulation of b-oxidation of long
chain fatty acids is not completely understood. Further studies
should reveal if conjugation with Ufm1 has any role in altering the
activity or signaling the translocation of the mitochondrial
trifunctional protein during this energy generation process.
Recently, a protein with a suggested role in membrane transport
was reported as the first identified target of human Ufm1
modification [26].
Our results showed that in L. donovani Ufm1, Uba5, and Ufc1
are found associated with the mitochondrion. In addition, both the
targets for Ufm1 conjugation that we identified in this study also
are associated with the mitochondrion. The presence of the
components of Leishmania Ufm1 pathway and its substrates argue
for the existence of a mitochondria associated Ufm1 conjugation
pathway. In contrast, subcellular localization of human Ufm1as
well as other components i.e., Uba5, Ufc1 or Ufl1 is not known
[24,26]. Previously E1, E2 of Ub or E3 of SUMO were shown
independently to be associated with mitochondria in metazoans
[34–36]. To our knowledge, this is the first report that
demonstrates the presence of complete Ufm1 pathway along with
its substrates in the mitochondria.
Mitochondrion associated Ufm1 conjugation in Leishmania
presents several interesting possibilities regarding biological
functions of this pathway. For example, ubiquitin involvement in
the degradation of mitochondrial matrix proteins is known [37].
Stability of several mammalian mitochondrial proteins is affected
by proteasomal inhibition suggesting a role for ubiquitination [38].
Several E3 ligases located on the outer mitochondrial membrane
have been identified recently that primarily affect the mitochon-
drial morphology by either ubiquitination [39] or by Sumoylation
of mammalian proteins that regulate mitochondrial fission [35]. It
would be of interest to investigate whether the changes mediated
by the Ufm1 conjugation have any impact on the life-cycle related
differentiation of the parasites.
Demonstration of the existence of mitochondria associated
Ufm1 conjugation in unicellular trypanosomatid parasites offers
unique possibilities to explore the importance of this pathway in
the context of its pathogenesis and host-parasite adaptations.
Importantly, the ubiquitin-dependent proteolysis system (UPS) is
increasingly recognized as a viable therapeutic pathway in the
treatment of cancer after the successful treatment of hematological
malignancies with proteasome inhibitors [40]. Deubiquitinases,
the key effectors of UPS and intracellular signaling cascades, and
Ub ligases because of their narrow substrate specificity are
emerging as important targets for potential anticancer therapies
[41,42]. Identification of Ufm1 mediated protein modification
pathways in Leishmania, with its distinct subset of substrate proteins
associated with mitochondrial activities as demonstrated in this
report may provide specific targets for novel drug therapies against
this human pathogen.
Materials and Methods
Plasmids and parasite cultures
Leishmania donovani promastigotes (strain 1S, clone 2D, WHO
designation: MHOM/SD/62/1S-CL2D) were grown in M199
medium containing 10% heat inactivated fetal bovine serum.
Promastigotes were transfected by electroporation and selected for
growth in medium containing Geneticin (G418) up to 100 mg/ml
or Hygromycin up to 50 mg/ml or both. These drug-resistant cells
were used in all subsequent experiments. The Leishmania
expression plasmid pKSNeo [43] was used to express either the
full-length or where indicated, the mutant forms of L. donovani
Ufm1, Uba5 or Ufc1 in transfected Leishmania parasites. For this
purpose, the full-length gene encoding L. donovani Ufm1 was
amplified with oligos based on the L. infantum putative Ufm1
sequence. The point mutation G98A was introduced by PCR to
generate Ufm1 mutants. These oligos introduced a FLAG tag at
the C’ terminus of the fusion protein and contained SpeI restriction
sites on either end. The SpeI insert was subcloned into the SpeI site
of pKSNeo, resulting in plasmid constructs that were used to
overexpress wild type or mutant Ufm1 in Leishmania transfectants.
For co-expression experiments pXGHYG plasmid was used [44].
Bacterial expression of LdUba5, LdUfc1 and TbUfm1
Wild type LdUba5, LdUfc1 and TbUfm1 were amplified by
PCR and ligated into pCR T7/CT-Topo (Invitrogen). The
recombinant proteins were expressed from E. coli and purified in
native conditions through Ni-agarose column chromatography
according to the manufacturer’s protocol (Qiagen). The recombi-
nant purified LdUba5, LdUfc1 and TbUfm1 proteins were used to
generate polyclonal antibodies in rabbits according to the
manufacturer’s protocol (Spring Valley Laboratories, Woodbine,
MD).
Ufm1 activation by LdUba5
Human recombinant Ufm1 and Uba5 were purchased from
Boston Biochem, Cambridge, MA. Leishmania Uba5, Ufm1 wild
type and mutant Uba5 and Ufm1 proteins were immunoprecip-
itated from the respective transfectants using anti-HA affinity gel.
These immunoprecipitated proteins were used in combinations in
a fluorescent polarization assay (Transcreener AMP/GMP Assay)
using reagents purchased from Bell Brook labs, Madison, WI and
FP measurements were obtained from Spectramax M5 fluores-
cence spectrometer. The Transcreener AMP/GMP Assay allows
measurement of any enzymatic activity that produces AMP. The
fluorescent signal is emitted by an AMP/GMP Alexa633 tracer
bound to an AMP/GMP Antibody. When the tracer is displaced
by the AMP generated during E1-like enzymatic activity, it results
in free rotation of the tracer leading to a decrease in polarization.
The amount of AMP released in the LdUfm1 activation is
proportional to the decrease in polarization.
Identification of conjugates of LdUfm1 by mass
spectrometric analysis
For immunoprecipitation analysis, 1610
8 Leishmania promasti-
gotes were lysed by 1 ml of NET buffer (150 mM NaCl, 1 mM
EDTA, 10 mM Tris–HCl, pH 7.5, 1% Nonidet P-40 with
protease inhibitor cocktail) and the lysate was centrifuged at
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of the lysate, 5 ml of anti-Flag-M2 antibodies (Sigma) were added
to the lysate and the mixture was incubated under constant
rotation over night at 4uC. The complexes were immunoprecip-
itated with 25 ml of Protein-A Sepharose beads by incubation
under constant rotation at 4uC for 1 hr. The precipitated
complexes were washed five times with ice-cold NET buffer and
eluted by boiling for 5 min in SDS sample buffer in the presence of
b-mercaptoethanol. The supernatant was subjected to SDS–
PAGE and analyzed by immunoblots with anti-Flag (M2) or anti-
HA antibody.
For purification of 6xHis-tagged proteins under denaturing
conditions, 2610
8 transfectant Leishmania promastigotes or axenic
amastigotes were lysed by 1 ml of denaturing lysis buffer (8M urea,
0.1M NaH2PO4, and 0.01M Tris-HCl, pH 8.0 with 20 mM N-
ethylmaleimide) and the lysate was sonicated briefly and then
centrifuged at 12000 rpm for 20 min at room temperature to
remove debris. To the supernatant, 30 ml of Ni-NTA Agarose
(Qiagen) was added and the mixture was incubated under constant
rotation for 30 min at room temperature. The precipitated
material was washed five times with denaturing wash buffer (8M
urea, 0.1M NaH2PO4, and 0.01M Tris-HCl, pH 5.9). The
complexes were eluted in elution buffer (8M urea, 0.1M
NaH2PO4, and 0.01M Tris-HCl, pH 4.5). The resulting lysates
were subjected to SDS-PAGE and analyzed by immunoblots with
a-TbUfm1.
Intracellular localization of LdUfm1, LdUba5, LdUfc1
Immunofluorescence assay was performed essentially as de-
scribed previously (Gannavaram et al., 2008). Briefly, the cells
were preincubated with Mitotracker Red (Invitrogen) to label the
mitochondria. Rabbit polyclonal antibodies raised against bacte-
rially expressed TbUfm1, LdUba5 or LdUfc1 proteins were used
to detect LdUfm1, LdUba5, LdUfc1 in Leishmania promastigotes to
determine the cellular localization of endogenous proteins in these
cells.
Macrophage infection
Human elutriated monocytes were resuspended at 1.8610
5
cells/ml in RPMI medium containing 10% FBS macrophage
colony-stimulating factor (20 ng/ml, ProSpec, Israel), plated in
0.5 ml on eight-chamber Lab-Tek tissue-culture slides (Miles
Laboratories) and incubated for 9 days for differentiation into
macrophages. The macrophage infection experiments were
performed essentially as described earlier [28].
Supporting Information
Figure S1 Trypanosomatid parasite genomes contain
homologs of mammalian Ufm1. CLUSTAL W alignment of
Leishmania donovani, Trypanosoma brucei and Trypanosoma cruzi putative
Ufm1 with the mammalian homolog. The shaded area represents
identical residues, and dashes represent gaps. The C’terminal
glycine, essential residue for the substrate conjugation is indicated
with arrow mark. The percentage identities of full-length L.
donovani Ufm1 with those of T. brucei, T. cruzi and human Ufm1 are
shown in the parentheses.
(TIF)
Figure S2 Trypanosomatid parasite genomes contain
homologs of mammalian Uba5 5. Sequence alignment of
Leishmania donovani, Trypanosoma brucei and Trypanosoma cruzi putative
Uba5 with the mammalian homologs. The shaded area represents
identical residues, and dashes represent gaps. The ATP-binding
motif involving the residues GXGXXG is indicated with a solid
line. The putative active site Cys residue is indicated with an
asterisk. The metal-binding motif is indicated with a dotted line.
The percentage identities of full-length L. donovani Uba5 with those
of T. brucei, T. cruzi and human Uba5 are shown in the
parentheses.
(TIF)
Figure S3 Trypanosomatid parasite genomes contain
homologs of mammalian Ufc1. CLUSTAL W alignment of
Leishmania donovani, Trypanosoma brucei and Trypanosoma cruzi putative
Ufc1 with the mammalian homolog. The shaded area represents
identical residues, and dashes represent gaps. The putative active
site Cys residue is indicated with an asterisk. The percentage
identities of full-length L. donovani Ufm1 with those of T. brucei, T.
cruzi and human Ufc1 are shown in the parentheses.
(TIF)
Figure S4 Purification of LdUfm1 conjugates from
LdUfm1 transfectant amastigotes. (A) Leishmania transfectant
cells expressing HA-6xHis-Ufm1 or HA-6xHis-Ufm1
G98A or the
non-conjugatable HA-6xHis-Ufm
DC were lysed under denaturing
conditions and the conjugates were precipitated with Ni-agarose
beads. The eluates from the beads were subjected to SDS-PAGE
and the immunoblots were probed with anti-Ufm1 antibodies and
scanned on a LiCor odyssey instrument. The conjugates are
indicated with asterisk and the unconjugated Ufm1 is indicated
with arrows.
(TIF)
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